These Alzheimer’s Drugs Were Supposed to Revolutionize the Way We Fight the Disease. The Reality Is More Complicated.

Why It Matters

If the drugs deliver only marginal benefits, insurers, clinicians, and investors must reassess treatment protocols and valuation models, potentially reshaping the Alzheimer’s‑drug market.

Key Takeaways

• Cochrane review finds Leqimbi, Kisunla show negligible cognitive benefit.
• Report labels 18‑month effects as “trivial” for both drugs.
• Over 7 million U.S. seniors diagnosed with Alzheimer’s in 2025.
• Market expectations face backlash from clinicians and insurers.
• Potential slowdown in Alzheimer‑drug pipeline funding and stock valuations.

Pulse Analysis

The Alzheimer’s epidemic continues to strain families and the health‑care system, with the Alzheimer’s Association estimating 7.2 million U.S. seniors affected in 2025. In response, pharmaceutical firms rushed two high‑priced biologics—Leqimbi and Kisunla—into the market, promising to alter disease trajectory. Early enthusiasm was fueled by accelerated FDA approvals and aggressive marketing, positioning the drugs as the first disease‑modifying options in decades. Investors poured capital into biotech firms, while payers prepared for higher reimbursement demands.

The Cochrane Library’s systematic review, however, paints a sobering picture. By aggregating data from several randomized controlled trials, the analysis reveals that neither drug yields statistically or clinically meaningful gains in cognition, functional independence, or overall dementia severity after 18 months. The term “trivial” underscores the gap between trial endpoints and real‑world patient outcomes. Clinicians, already cautious about side‑effect profiles and infusion logistics, may now prioritize non‑pharmacologic interventions and existing symptomatic treatments. Payers are likely to tighten coverage criteria, demanding robust evidence of cost‑effectiveness before approving widespread use.

Beyond the bedside, the findings reverberate through capital markets and research pipelines. Shares of companies tied to Leqimbi and Kisunla have experienced heightened volatility, prompting analysts to downgrade earnings forecasts. Venture capital may shift toward next‑generation approaches—such as gene therapy, anti‑amyloid vaccines, or precision‑medicine platforms—rather than incremental biologics. The episode also serves as a cautionary tale for regulators, emphasizing the need for post‑approval surveillance and transparent efficacy benchmarks. Ultimately, realistic expectations and rigorous evidence will be essential to restore confidence in Alzheimer’s therapeutics and guide sustainable investment.